 |
June 8, 2009
Y's Therapeutics Co., Ltd. appointed Susumu Yamada as board member&CBO, and Akira Murakami & Yoshihiro Ito as Auditors on June 8, 2009.
|
 |
|
May 16, 2009
Y’s Therapeutics Co., Ltd have been reduced the paid-in capital and capital reserve.
|
|
|
March 31, 2009
In appointing about the Board of directors and the Auditors.
|
|
|
January 8, 2009
An internet site, Science-Business eXchange which was managed by BioCentury and Nature published that YSPSL would be a potent anti-elilepsy drug.
|
|
|
November 5, 2008
Y’s Therapeutics Announces Acceptance of CTA
to conduct Phase I/II Clinical Trial of YSCMA in France
|
|
|
September 16, 2008
Y's Therapeutics Completes Phase IIa Trial with YSPSL
in Kidney Transplant Patients for Prevention of Ischemic Reperfusion Injury (IRI)
|
|
|
September 10, 2008
Conclusion of Exclusive Licensing Agreement of YSCMA, Humanized Anti-CD26
Monoclonal Antibody, for Development and Sales in Japan
|
|
|
April 1, 2008
In appointing about the Board of directors and the Auditors
|
|
|
February 14, 2008
Y's Therapeutics announces FDA acceptance of IND to conduct Phase I clinical trial for
YSCMA in the USA
|
|
|
January 15, 2008
We have update the employment information at the our website.
|
|
|
More
|
|
